Mar 27, 2019 - Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
Mar 21, 2019 - The big biotech's pivot from multiple sclerosis to Alzheimer's disease was dealt a decisive blow today.
Mar 21, 2019 - Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.
Mar 15, 2019 - Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Mar 13, 2019 - Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.
Mar 12, 2019 - Eli Lilly (LLY) closed at $123.50 in the latest trading session, marking no change from the prior day.
Mar 08, 2019 - Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.
Mar 06, 2019 - Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
Mar 06, 2019 - J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression
Mar 06, 2019 - Pharmaceutical companies are suddenly eager to lower drug prices.